Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036647 · ClinicalTrials.gov registry record · Phase 3
OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by OSI Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 731
- Enrollment target
NCT00036647 is a Phase 3 study that has completed, run by OSI Pharmaceuticals. The registered enrollment target is 731 participants.
The verdict
NCT00036647, a Phase 3 study, has completed, sponsored by OSI Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 731 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if OSI-774 will improve overall survival of patients with incurable stage IIIB/IV non-small cell lung cancer compared to standard of care. OSI-774 is a new type of drug under evaluation called an epidermal growth factor receptor (EGFR). OSI-774 is an investigational drug that has not yet been approved by the U.S. Food and Drug Administration (FDA).
Interventions
- DRUG Tarceva (erlotinib HCl, OSI-774 )
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 731 participants |
| Start Date | 2001-11-01 |
| Est. Completion | 2004-01-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00036647
The ClinicalTrials.gov registry entry for NCT00036647 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 731 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OSI Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tarceva (erlotinib HCl, OSI-774 ) is the first listed.
NCT00036647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00036647 about?
NCT00036647 is a clinical study titled "OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer". The purpose of this study is to determine if OSI-774 will improve overall survival of patients with incurable stage IIIB/IV non-small cell lung cancer compared to standard of care. OSI-774 is a new type of drug under evaluation called an epidermal growth factor receptor (EGFR). OSI-774 is an investi...
What is the current status of trial NCT00036647?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 731 participants. The study started on 2001-11-01. Estimated completion is 2004-01-30.
What interventions are being tested in trial NCT00036647?
The interventions under investigation include: Tarceva (erlotinib HCl, OSI-774 ) (DRUG).
Who is sponsoring clinical trial NCT00036647?
This trial is sponsored by OSI Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.